<bill session="115" type="s" number="1276" updated="2019-04-18T16:36:45Z">
  <state datetime="2017-05-25">REFERRED</state>
  <status>
    <introduced datetime="2017-05-25"/>
  </status>
  <introduced datetime="2017-05-25"/>
  <titles>
    <title type="official" as="introduced">A bill to require the Attorney General to make a determination as to whether cannabidiol should be a controlled substance and listed in a schedule under the Controlled Substances Act and to expand research on the potential medical benefits of cannabidiol and other marihuana components.</title>
    <title type="short" as="introduced">Cannabidiol Research Expansion Act</title>
    <title type="short" as="introduced">Cannabidiol Research Expansion Act</title>
    <title type="display">Cannabidiol Research Expansion Act</title>
  </titles>
  <sponsor bioguide_id="F000062"/>
  <cosponsors>
    <cosponsor bioguide_id="D000563" joined="2017-05-25"/>
    <cosponsor bioguide_id="E000295" joined="2017-05-25"/>
    <cosponsor bioguide_id="G000386" joined="2017-05-25"/>
    <cosponsor bioguide_id="K000384" joined="2017-11-08"/>
    <cosponsor bioguide_id="K000367" joined="2018-03-19"/>
    <cosponsor bioguide_id="T000476" joined="2017-05-25"/>
    <cosponsor bioguide_id="W000802" joined="2017-07-11"/>
  </cosponsors>
  <actions>
    <action datetime="2017-05-25">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2017-05-25" state="REFERRED">
      <text>Read twice and referred to the Committee on the Judiciary.</text>
      <reference ref="CR S3220-3221" label="Sponsor introductory remarks on measure"/>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSJU" name="Senate Judiciary" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Crime and law enforcement"/>
    <term name="Alternative treatments"/>
    <term name="Child health"/>
    <term name="Drug therapy"/>
    <term name="Drug trafficking and controlled substances"/>
    <term name="Education programs funding"/>
    <term name="Government studies and investigations"/>
    <term name="Health personnel"/>
    <term name="Health programs administration and funding"/>
    <term name="Higher education"/>
    <term name="Licensing and registrations"/>
    <term name="Medical education"/>
    <term name="Medical research"/>
    <term name="Neurological disorders"/>
    <term name="Research administration and funding"/>
    <term name="Trade restrictions"/>
  </subjects>
  <amendments/>
  <summary date="2017-05-25T04:00:00Z" status="Introduced in Senate">Cannabidiol Research Expansion Act

This bill requires the Drug Enforcement Administration (DEA) and the Department of Health and Human Services to each evaluate whether cannabidiol, the nonpsychoactive substance derived from marijuana or the synthetic formulation, should be a controlled substance under the Controlled Substances Act. After taking into consideration the evaluations, the DEA must initiate proceedings for classifying cannabidiol as a controlled substance if control is warranted.

The bill expands the authority for: (1) conducting medical research on cannabidiol and other nonpsychoactive components of marijuana, and (2) possessing or transporting cannabidiol or any other nonpsychoactive component of marijuana for certain medicinal purposes.

The Department of Justice shall register an applicant to manufacture or distribute cannabidiol or marijuana for the purpose of commercial production if approved by HHS.

Physicians who are licensed under state law may discuss the potential harms and benefits of cannabidiol or those components of marijuana as a treatment with their patients or the legal guardians of underage patients.

The bill terminates four years after enactment.</summary>
  <committee-reports/>
</bill>
